Building an autologous CAR-T manufacturing network from scratch: infrastructure, workforce, and what comes next

“I see a platform as something that combines all the different manufacturing processes, the digital infrastructure, and the full end-to-end operation, from apheresis in the hospital through production here and back to the hospital.”

Abi Pinchbeck, Commissioning Editor, Cell & Gene Therapy Insights , speaks with Frederik Buysse, General Manager/VP Europe, Legend Biotech, about the operational, technical, and workforce challenges of scaling autologous CAR-T manufacturing, including strategies for process standardization, cost reduction, supply network reliability, and building a specialist team from the ground up.

Please enter your email to access content Read now